venetoclax (venclexta) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Venetoclax (trade name Venclexta, also known as ABT-199) is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. BCL-2 and its related proteins BCL-XL and MCL-1 bind to and sequester pro-apoptotic signals in the cell, causing a down-regulation of apoptosis. As an oncogene and an important regulator of apoptosis, BCL-2 overexpression therefore results in increased tumor cell survival and resistance to chemotherapy. FDA approved Venetoclax in April 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. Also this drug in phase 3 clinical trial in combination therapy for the treatment patients with refractory myeloma and Acute Myeloid Leukemia. Common side effects include neutropenia, nausea, anemia, diarrhea, upper respiratory tract infection. Major side effects include tumor lysis syndrome and severe neutropenia.   NCATS

Chemistry

  • SMILES: CC1(C)CCC(CN2CCN(CC2)C3=CC=C(C(=O)NS(=O)(=O)C4=CC=C(NCC5CCOCC5)C(=C4)[N+]([O-])=O)C(OC6=CN=C7NC=CC7=C6)=C3)=C(C1)C8=CC=C(Cl)C=C8
  • InChIKey: LQBVNQSMGBZMKD-UHFFFAOYSA-N
  • Mol. Mass: 868.439
  • ALogP: 8.66
  • ChEMBL Molecule:
    venetoclax  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$5.2959 - $49.6009

United States

$7.2500 - $93.3978
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-n-((3-nitro-4-((tetrahydro-2h-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide | 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-n-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide | abt-0199 | abt199 | abt-199 | benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)- | gdc-0199 | rg7601 | rg-7601 | venclexta | venetoclax

Organizations (266)

Research & Development (265)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (87)

Approved Indications (1)


 

Leukemia, Lymphocytic, Chronic, B-Cell

Experimental Indications - Clinical Trial Phases 1-4 (87)


 

Adult (Phase 2)

Amyloidosis (Phase 2)

Anemia (Phase 1)

Antigens, CD (Phase 2)

Biomarkers (Phase 2)

B-Lymphocytes (Phase 1)

Bone Marrow Cells (Phase 2)

Bone Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Burkitt Lymphoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Castration (Phase 1/Phase 2)

Chromosome Aberrations (Phase 2)

Colorectal Neoplasms (Phase 2)

Cyclin D1 (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 2)

Drug Therapy (Phase 3)

Fusion Proteins, bcr-abl (Phase 2)

Geriatrics (Phase 2)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 2)

Hematopoietic Stem Cell Transplantation (Phase 2)

HIV Infections (Phase 1/Phase 2)

Hodgkin Disease (Phase 1/Phase 2)

Idiopathic Pulmonary Fibrosis (Early Phase 1)

Immunoglobulin Light-chain Amyloidosis (Phase 1/Phase 2)

Intracranial Arteriosclerosis (Phase 4)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 1)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Eosinophilic, Acute (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell ()

Leukemia, Lymphoid (Phase 3)

Leukemia, Monocytic, Acute (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 4)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1/Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Neutrophilic, Chronic (Phase 1/Phase 2)

Leukemia, Prolymphocytic, T-Cell (Phase 2)

Leukemia, Promyelocytic, Acute (Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Lymphohistiocytosis, Hemophagocytic (Phase 1)

Lymphoma (Phase 2/Phase 3)

Lymphoma, B-Cell (Phase 2/Phase 3)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2/Phase 3)

Lymphoma, Large-Cell, Anaplastic (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 3)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Multiple Myeloma (Phase 3)

Mutation (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 2)

Neoplasms ()

Neuroblastoma (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 1)

Philadelphia Chromosome (Phase 2)

Plasmacytoma (Phase 2)

Polycythemia Vera (Phase 1/Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Primary Myelofibrosis (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)

Risk Factors (Phase 2)

Salvage Therapy (Phase 2)

Sarcoma (Phase 1)

Sarcoma, Myeloid (Phase 1)

Small Cell Lung Carcinoma (Phase 1/Phase 2)

Squamous Intraepithelial Lesions (Phase 3)

Thrombocythemia, Essential (Phase 1/Phase 2)

Tissues (Phase 2)

Translocation, Genetic (Phase 2)

Tumor Suppressor Protein p53 (Early Phase 1)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 447
  • # of Trial Organizations: 265

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue